Akebia Therapeutics (AKBA) shares were down more than 14% in recent Thursday trading after the biopharmaceutical company reported a wider-than-expected Q4 loss.
Earlier, the company reported a Q4 net loss of $0.10 per diluted share. Analysts polled by FactSet expected a loss of $0.08.
Revenue for the quarter ended Dec. 31 was $46.5 million, down from $56.2 million a year earlier. Analysts surveyed by FactSet expected $37.3 million.
The company said it has sufficient funds to run its current operating plan for at least two years.
Price: 1.65, Change: -0.29, Percent Change: -14.77
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.